Comparison of AstraZeneca and sinopharm vaccines as boosters in protection against COVID-19 infection

Letafati, Arash; Eyvazzadeh, Nooshin; Gharehkhani, Amirhossein; Khorshidian, Ayeh; Chalabiani, Siavash; Soufiani, Elnaz Khodadoust; Khakpoor, Niloofar; Shamsodini, Benyamin; Beheshti, Taranom; Olyaei, Raha Taheri Bavili; Soleimani, Anahita; Melyani, Fatemeh; Hossein, Ghazal Mashhadi

doi:10.1016/j.biologicals.2023.101668

Cited by 5 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cellular and humoral immune responses to both mRNA and viral vector vaccines in the immunodeficient individuals were unprotective, suggesting a heterologous vaccine strategy among such population 46 . Yet, heterologous booster dose does not guarantee improved protection, study identifies 47 . The protection levels of booster dose of various vaccines varied.…”

Section: Future Research and Possible Interventionsmentioning

confidence: 97%

“…46 Yet, heterologous booster dose does not guarantee improved protection, study identifies. 47 The protection levels of…”

Section: Future Research and Possible Interventionsmentioning

confidence: 99%

“… 46 Yet, heterologous booster dose does not guarantee improved protection, study identifies. 47 The protection levels of booster dose of various vaccines varied. Vaccine cocktails like bivalent original prototype virus+omicron BA.4/5 subvariants and original prototype virus+omicron BA.1 subvariant vaccine combinations demonstrated positive results in clinical trials, and are approved for human use ( https://healthcare-in-europe.com/en/news/cocktail-vaccines-protect-future-covid-19-variants.html ).…”

Section: Future Research and Possible Interventionsmentioning

confidence: 99%

See 2 more Smart Citations

COVID‐19 vaccines and their underbelly: Are we going the right way?

Satapathy,

Pattnaik,

Sahoo

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

BackgroundHistorically, a critical aetiological agent of health concern stays till eternity after its discovery, so shall it be with the COVID‐19 outbreak. It has transformed human life to a ‘new normal’ with huge tolls on the social, psychological, intellectual and financial spheres.AimThis perspective aimed to collate numerous reported COVID‐19 vaccine‐associated adverse events and the predisposing factors. It focussed on the efficacy of mix‐n‐match (cocktail) vaccines to effectively counter COVID‐19 infection to facilitate future research and possible interventions.Material and MethodsDatabases like Scopus, Pubmed and the Web‐of‐science were searched for published literature on ‘adverse events associated with COVID‐19 vaccine’. The reports and updates from health agencies like the WHO and CDC were also considered for the purpose. The details with respect to the adverse events associated with COVID‐19 vaccination and the predisposing factors were compiled to obtain insights and suggest possible future directions in vaccine research.ResultsIndia stood strong to manage its health resources in time and turned into a dominant global vaccine supplier at a time when healthcare infrastructure of many countries was still significantly challenged. Developing indigenous vaccines and the vaccination drive in India were its major achievements during the second and the subsequent COVID‐19 waves. The fully indigenous Covaxin vaccine, primarily as an emergency intervention, was successfully rapidly launched. Similar such vaccines for emergency use were developed elsewhere as well. However, all of these reached the marketplace with a ‘emergency use only’ tag, without formal clinical trials and other associated formalities to validate and verify them as these would require much longer incubation time before they are available for human use.DiscussionMany adverse events associated with either the first or the second/booster vaccination doses were reported. Evidently, these associated adverse events were considered as ‘usually rare’ or were often underreported. Without the additional financial or ethical burden on the vaccine companies, fortunately, the Phase IV (human) clinical trials of their manufactured vaccines are occurring by default as the human population receives these under the tag ‘emergency use’. Thus, focused and collaborative strategies to unveil the molecular mechanisms in vaccine‐related adverse events in a time‐bound manner are suggested.ConclusionReliable data particularly on the safety of children is lacking as majority of the current over‐the‐counter COVID‐19 vaccines were for emergency use. Many of these were still in their Phase III and Phase IV trials. The need for a mutant‐proof, next‐gen COVID‐19 vaccine in the face of vaccine‐associated adverse events is opined.

show abstract

Section: Future Research and Possible Interventionsmentioning

confidence: 97%

“…46 Yet, heterologous booster dose does not guarantee improved protection, study identifies. 47 The protection levels of…”

Section: Future Research and Possible Interventionsmentioning

confidence: 99%

Section: Future Research and Possible Interventionsmentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 vaccines and their underbelly: Are we going the right way?

Satapathy,

Pattnaik,

Sahoo

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…In a study done where persons initially received two doses of Sinopharm, a booster was administered of either Sinopharm or AstraZeneca. The findings displayed that individuals receiving the AstraZeneca booster developed a stronger antibody and CD8 + T cell response and thus were better protected by the AstraZeneca vaccine [35].…”

Section: Oxford-astrazenecamentioning

confidence: 97%

Effectiveness and Safety of COVID-19 Vaccines, including Vaccination Issues in Trinidad and Tobago: A Systematic Review

Justiz-Vaillant,

Roopnarine,

Solomon

et al. 2024

Preprint

View full text Add to dashboard Cite

Vaccination against the SARS-CoV2 virus has shown great promise in managing the spread and severity of Covid-19. While these vaccines were able to provide a favourable response in controlling the SARS-CoV2 infection, its use came with accompanying side effects. This systematic review aimed to determine the effectiveness of the different Covid-19 vaccine subtypes and discover the side effects associated with each vaccine elsewhere but specially in Trinidad and Tobago. For this systematic review, the keywords “Pfizer-BioNTech OR Moderna OR Oxford-AstraZeneca OR Janssen OR Sinopharm OR Novavax AND Covid-19 vaccine efficacy” and “Covid-19 vaccines AND Trinidad and Tobago” were researched under PubMed, MEDLINE and other internet sources through which other notable journals, and documents were discovered and searched similarly as outlined previously. In doing so, 65 relevant articles were included as part of this review. Of the studies examined, overall the vaccine with the greatest VE was found to be Pfizer-BioNTech (95%), followed by Moderna (94.1%), Novavax (89.7%), AstraZeneca (70.4%), Sinopharm (67%) and finally Janssen (66.9%). The use of Pfizer-BioNTech or Moderna was most efficacious in response to the different Covid-19 variants. Some side effects were common for all vaccine types however adverse effects were more commonly seen with vaccination by mRNA vaccines, Pfizer-BioNTech and Oxford-Astrazeneca. Researchers targeted individuals aged 18 and above residing in various geographical areas of TT, specifically focusing on those who had not received the COVID-19 vaccine and expressed hesitancy towards it. Convenience sampling was used to select the study participants, and formal in-depth virtual interviews were conducted on a one-to-one basis, employing a semi-structured questionnaire to guide the discussions. The interviews were meticulously recorded and transcribed, following the principles of reflexive thematic analysis, to distill key insights from the participants' responses. The study's findings, derived from the perspectives of 25 participants, illuminated a complex tapestry of reasons underlying vaccine hesitancy in Trinidad and Tobago. Notably, prominent themes emerged, including fear, doubts regarding vaccine efficacy, a perceived inadequacy of information, a sense of susceptibility to the virus, deep-seated mistrust, alternative herbal remedies, and religious reservations. Interestingly, the motivations expressed by these vaccine-hesitant individuals for potentially receiving the vaccine in the future were rooted in notions of necessity, an increased sense of susceptibility to the virus, a desire to reach a certain health benchmark, and a need for assurance regarding the vaccine's safety and effectiveness. This comprehensive exploration of vaccine hesitancy in TT provides valuable insights for public health officials and policymakers in crafting targeted strategies to address this critical issue within the local context. Conclusion: The findings of this study determined that vaccination against the SARS-CoV2 virus provided beneficial outcomes against infection, Covid-19 related hospitalizations, ICU admissions and mortality. While vaccination was deemed highly appropriate in managing the spread of the SARS-CoV2 virus and enhancing the outcomes in infected persons, the effectiveness of the different vaccine platforms indicated that certain vaccine platforms are preferential to others in different populations. In terms of vaccine efficacy, nucleic acid vaccines such as Pfizer-BioNTech and Moderna showed the greatest effectiveness while inactivated whole virus vaccines such as Sinopharm and viral vectors like Janssen had the least effectiveness. The side effects, joint/muscle soreness, pain at the injection site, shoulder pain, headaches, fever, chills, weakness, epistaxis, renal and certain cardiovascular events were common for all vaccine types. Adverse effects were more frequent and severe with the mRNA vaccines by Pfizer-BioNTech and Oxford-Astrazeneca than inactivated whole virus vaccines. The data collected in this research can be very useful to help individuals make a decision on which vaccine would be appropriate for them. More long-term studies are needed to better gauge the scope of side effects for each vaccine type.

show abstract

“…The virus can lead to various symptoms which differ in severity among those affected (1). The primary symptoms of the disease include fever, cough, and difficulty breathing (2). Other respiratory symptoms, such as sore throat, might also occur (3).…”

Section: Introductionmentioning

confidence: 99%

Distinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus

Aboofazeli,

Mondeali,

Tajdini

et al. 2024

Arch Neurosci

Self Cite

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a virus in the coronaviridae, has caused a global pandemic with various symptoms and complications. Among the groups affected by this virus are individuals with multiple sclerosis (MS), a chronic autoimmune disorder that affects the primary central nervous system (CNS). Understanding coronavirus disease 2019’s (COVID-19) impact on MS patients is crucial for optimizing patient management and developing targeted therapies due to the challenges it presents. Objectives: The primary purpose of this study was to investigate the respiratory and neurology symptoms of COVID-19 in patients with MS in comparison to the non-infected group. Furthermore, this study examined how age and gender might affect the symptoms of contracting COVID-19 and the mortality rate in patients with MS. Methods: The data were collected from six hospitals within the Iranian Network for Research in Viral Diseases (INRVD) between March 2020 and July 2021. A total of 63 individuals diagnosed with MS were examined, with 30 testing positive for both COVID-19 and MS; however, 33 individuals were positive only for MS. These individuals had presented at the hospital experiencing respiratory symptoms, including rhinorrhea, difficulty breathing, and cough. Various clinical aspects were evaluated, including age, gender, and the presence of COVID-19 symptoms. Statistical analyses included the Mann-Whitney t-test, Fisher’s exact test, and odds ratio calculations using SPSS-27 and R 4.2.3. Results: The study encompassed 63 MS patients, with 29 (46%) and 34 (54%) males and females, respectively. Of these patients, 30 individuals were positive for COVID-19. Most subjects were from Tehran province, Iran. Patients in the case group were significantly younger than those in the control group. Notably, dizziness, breath shortness, and vomiting were significantly more prevalent in MS patients following COVID-19. Conclusions: This study highlights the distinct clinical presentation of COVID-19 in individuals with MS. Dizziness, breath shortness, vomiting, and increased mortality were significantly associated with MS patients with COVID-19. The aforementioned findings underscore the importance of tailored management strategies for this unique patient population following the disease.

show abstract

Comparison of AstraZeneca and sinopharm vaccines as boosters in protection against COVID-19 infection

Cited by 5 publications

References 46 publications

COVID‐19 vaccines and their underbelly: Are we going the right way?

COVID‐19 vaccines and their underbelly: Are we going the right way?

Effectiveness and Safety of COVID-19 Vaccines, including Vaccination Issues in Trinidad and Tobago: A Systematic Review

Distinct Clinical Manifestations of COVID-19 in Multiple Sclerosis Patients: Unraveling the Clinical Nexus

Contact Info

Product

Resources

About